Investor Relations

Yesterday, 3 December 2025, Ambu A/S held its annual general meeting, at which the following items were adopted:

Approval of the Company’s Annual Report and consolidated financial statements 
The presented audited Annual Report for the financial year 2024/25 was adopted by the shareholders.

Approval of the Remuneration Report 
The proposed and presented Remuneration Report for the financial year 2024/25 was adopted by the shareholders.

Approval of the appropriation of profit in accordance with the adopted Annual Report 
The Ambu Group reported a net profit for the year of DKK 609 million.

The Board of Directors proposed a dividend of DKK 0.41 per share of nominally DKK 0.50 so that a dividend in the total amount of DKK 110 million be paid out of the net profit for the year, corresponding to 18% of the Group’s net profit, whereas the remaining part of the net profit be carried forward to next year.

Approval of the Board of Directors' remuneration for the financial year 2025/26 
The Board of Directors proposed that the Board of Directors’ remuneration for the current financial year (2025/26) remained unchanged, compared to the previous financial year, and be stipulated as follows:

• Ordinary members of the Board of Directors receive basic remuneration amounting to DKK 400,000.
• The Chair receives three times the basic remuneration (DKK 1,200,000).
• The Vice Chair receives twice the basic remuneration (DKK 800,000).
• In addition, each member of a Board committee receives remuneration of DKK 132,000 per committee seat, however, the Chair of a Board committee receives remuneration of DKK 200,000 per chairmanship.

Election of Chair of the Board of Directors 
Jørgen Jensen was re-elected as Chair of the Board of Directors.

Election of Vice Chair of the Board of Directors 
Shacey Petrovic was re-elected as Vice Chair of the Board of Directors.

Election of other members of the Board of Directors 
David Hale, Simon Hesse Hoffmann, Susanne Larsson, and Michael del Prado were re-elected as members of the Board of Directors.

Election of auditor 
EY Godkendt Revisionspartnerselskab was appointed as the Company’s auditor in respect of statutory financial reporting as well as assurance engagements relating to sustainability reporting. 

Approval of the option to conduct general meetings in English (Article 24 of the Articles of Association)
The proposal to amend Article 24 of the articles of association to make it possible to conduct the company’s general meetings in Danish or English pursuant to the Board of Directors’ decision was adopted.

Authorization to the Chair of the meeting     
The Chair of the meeting was, with full right of substitution, authorized to apply for registration of the resolutions passed and to make any such amendments thereto as the Danish Business Authority or other authorities may require or request as a condition for registration or approval, as well as to continuously make and apply for registration of linguistic and other non-substantive adjustments to the company’s Articles of Association.

---------------------

Meeting adjourned.

Following the launch of Ambu® SureSight™ Connect in the U.S. and Great Britain in the first half of 2025, Ambu now expands its video laryngoscope portfolio with Ambu® SureSight™ Mobile – a video laryngoscope with an integrated screen for emergent and unplanned intubations across clinical settings.

Today, Ambu announces the introduction of SureSight Mobile, a portable video laryngoscope solution that expands and brings next-level flexibility to Ambu’s video laryngoscope portfolio.

Designed to be robust, reliable, and durable, the SureSight Mobile features an integrated screen without the need for separate monitors or cables. This all-in-one design enables clinicians to perform emergent and unplanned intubations swiftly and confidently in demanding environments – whether in an ambulance, emergency room, or remote location – making the SureSight Mobile a solution targeted for both pre-hospital and hospital settings. This versatile solution delivers high-quality imaging, empowering clinicians to not only visualize the airway with clarity but also seamlessly document and review the intubation process.

"There is now overwhelming evidence that video laryngoscopy enhances both the safety and efficacy of tracheal intubation compared with direct laryngoscopy. The recently published DAS 2025 Intubation Guidelines recommend that video laryngoscopes be used as the first-line approach for tracheal intubation whenever feasible. The launch of the SureSight Mobile is therefore extremely timely, enabling universal access to video laryngoscopy for all intubations across the hospital environment."

DR. IMRAN AHMAD¹
Consultant Anesthetist, Guy's & St Thomas' NHS Foundation Trust, London, UK            

Expanding and leveraging Ambu’s video laryngoscope portfolio
In the U.S. alone, the video laryngoscope market represents roughly DKK 4 billion and is growing 15-20% annually. Today, around 50% of all endotracheal intubations are performed with a video laryngoscope, making it the preferred intubation method across clinical settings. To support this development, Ambu’s expanded video laryngoscope portfolio now offers two SureSight video laryngoscope solutions, including a comprehensive range of 10 blades of different sizes. The breadth of Ambu’s video laryngoscope portfolio ensures that clinicians have a SureSight video laryngoscope for every setting, scenario, and preference – obtaining flexibility, reliability, and confidence across the continuum of care.

Ambu will now engage in a controlled market release phase, collaborating with clinicians at key hospitals across the U.S. and Great Britain, to evaluate the performance of the SureSight Mobile in clinical settings. Subsequently, Ambu will engage in a full launch in 2026.

"With the launch of SureSight Mobile, Ambu is reinforcing our leadership in the Respiratory market. By expanding our portfolio with a mobile video laryngoscope solution, we are addressing the needs clinicians face during unexpected intubation – when time matters most. This innovation reflects our commitment to delivering a comprehensive Respiratory offering of advanced solutions that empower healthcare professionals to make fast, confident decisions and uphold the highest standards of care across clinical settings."

BRITT MEELBY JENSEN
Chief Executive Officer, Ambu

-----------------------------------------------------------------------------------

¹ Dr. Ahmad has not been compensated for his quote in this press release.

Download the press release here

Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.

The attached document discloses the data of the transactions made by Executive Management.